| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/26/2006 | US20060241186 Alkylating agent combinations in the treatment of cancer |
| 10/26/2006 | US20060241178 Compositions and methods for treating lung cancer |
| 10/26/2006 | US20060241131 Pyrrolo[2,3-d]pyrimidine compounds |
| 10/26/2006 | US20060241074 Methods for treatment of pain |
| 10/26/2006 | US20060241073 Means and methods for counteracting fatty acid accumulation |
| 10/26/2006 | US20060241070 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treament of cancer |
| 10/26/2006 | US20060241069 Treatment of hyperproliferative disease |
| 10/26/2006 | US20060241068 Cardiac failure, cardiomegaly, myocarditis, cardiomyopathy, arteriosclerosis, arteriosclerosis obliterans, or ischemic heart disease |
| 10/26/2006 | US20060241067 Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| 10/26/2006 | US20060241066 Decoy composition for treating and preventing inflammatory disease |
| 10/26/2006 | US20060241057 provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include peptidyl allyl sulfone compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro. |
| 10/26/2006 | US20060241056 Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation |
| 10/26/2006 | US20060241055 Peptides promoting cell adherence, growth and secretion |
| 10/26/2006 | US20060241054 Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia |
| 10/26/2006 | US20060241053 Compounds and their analgesic applications |
| 10/26/2006 | US20060241052 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 10/26/2006 | US20060241051 Metastin derivatives and use thereof |
| 10/26/2006 | US20060241050 Use of a polyarginine such as hexa-L-arginine as an antitumor and antimetastatic agents; hexaarginine small enough to be nonimmunogenic |
| 10/26/2006 | US20060241049 below the kneecap in a diabetic subject; administering agonist of the non-proteolytically activated thrombin receptor |
| 10/26/2006 | US20060241048 Modified therapeutic agents |
| 10/26/2006 | US20060241047 FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and |
| 10/26/2006 | US20060241046 Peptide for use in the treatment of parasitic, brain, nervous system, psychological and viral disorders |
| 10/26/2006 | US20060241045 Method for producing preparation containing bioactive substance |
| 10/26/2006 | US20060241042 Calcineurin activators |
| 10/26/2006 | US20060241041 Fvii or fviia gla domain variants |
| 10/26/2006 | US20060241040 Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling |
| 10/26/2006 | US20060241039 reduce blood clotting activity by reducing thrombin generation; thrombotic diseases |
| 10/26/2006 | US20060241038 Therapeutic agent for Abeta related disorders |
| 10/26/2006 | US20060241037 Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs |
| 10/26/2006 | US20060241036 Soluble human interleukin 18 receptor-alpha, method of assaying the same, assay kit and medicinal composition |
| 10/26/2006 | US20060241035 Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome |
| 10/26/2006 | US20060241034 Means for preventing and treating cellular death and their biological applications |
| 10/26/2006 | US20060241032 Cell support comprising immobilized collagen/intergin fusion and a argine-glycine-aspartic acid (RGD) motif for use as scaffold to propagate implant or transplant materials; improving drug delivery systems; inhibition of tumor metastasis; tissue engineering |
| 10/26/2006 | US20060241031 Assay |
| 10/26/2006 | US20060241030 Irs modulators |
| 10/26/2006 | US20060241029 administering to an individual a therapeutically or prophylactically effective dosage regime of a hypocretin or an agonist thereof, and monitoring the condition of the individual responsive to the administering |
| 10/26/2006 | US20060241028 Respiratory system disorders; lung hypotensive agents; also pituitary adenylate cyclase activating peptide |
| 10/26/2006 | US20060241026 Novel cyclic peptides and use thereof as anti-microbial agents |
| 10/26/2006 | US20060241025 Biodegradable glucosamine-muramyl peptides for apoptosis modulation |
| 10/26/2006 | US20060241024 Intermediate for preparing glycopeptide derivatives |
| 10/26/2006 | US20060241023 Diabetic therapy; administering to patient an inhibitor of enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate |
| 10/26/2006 | US20060241022 Selectin targeting bioconjugates |
| 10/26/2006 | US20060241021 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 10/26/2006 | US20060241020 Protein tyrosine phosphatase inhibitors |
| 10/26/2006 | US20060241019 Long lasting insulin derivatives and methods thereof |
| 10/26/2006 | US20060241018 Linkers for radiopharmaceutical compounds |
| 10/26/2006 | US20060241017 Novel compounds with high therapeutic index |
| 10/26/2006 | US20060241016 For isolating low molecular weight peptides from animal tissue; prevention of initial dissolution of higher molecular weight fraction proteins by in situ denaturation within the tissue, by an organic solvent (preferably ethanol), prior to aqueous extraction |
| 10/26/2006 | US20060241015 Cancer genes |
| 10/26/2006 | US20060240526 Amino acid substitution in position 36; brain bleeding, hemorrhage, trauma or injury; genetic engineering and expression; biodrugs, anticoagulants |
| 10/26/2006 | US20060240525 Factor VII or VIIa - Like Molecules |
| 10/26/2006 | US20060240524 Conjugate comprising polypeptide with N-glycosylation site and sugar; increase blood clot formation for treatment of thrombocytopenia and hemophilia |
| 10/26/2006 | US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity |
| 10/26/2006 | US20060240519 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 10/26/2006 | US20060240517 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240512 Inducing oocyte activation by administering sperm perinuclear theca protein 34; interacts with tyrosine kinase; enhancing fertility; treating or diagnosing diminished fertility and abnormal spermiogenesis, providing contraception; identifying contraceptive and fertility-enhancing agents |
| 10/26/2006 | US20060240500 Diagnosis of kidney damage and protection against same |
| 10/26/2006 | US20060240494 Biocidal molecules, macromolecular targets and methods of production and use |
| 10/26/2006 | US20060240475 Detection of toxic gluten oligopeptides refractory to digestion by using antibodies and T cells responsive thereto; producing the antibodies by immunization of an animal |
| 10/26/2006 | US20060240464 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 10/26/2006 | US20060240446 Novel human cytomegalovirus DNA sequences |
| 10/26/2006 | US20060240436 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| 10/26/2006 | US20060240417 Agent controlling the apoptosis induction by p73 |
| 10/26/2006 | US20060240414 Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 10/26/2006 | US20060240410 Retroviral protease inhibitor combinations |
| 10/26/2006 | US20060240116 Bioactive factors in wound healing topical compositions and methods |
| 10/26/2006 | US20060240115 Composition against injection with and process for producting the same |
| 10/26/2006 | US20060240114 Drug for treating hemophilia and method of treating hemophilia using the same |
| 10/26/2006 | US20060240113 Anticancer agents; prevent forming blood vessels; removal blockager |
| 10/26/2006 | US20060240110 electrospun into fibers permitting immobilization and long-term delivery of biodrugs; compatibilizing polyoxyethylene glycol and low molecular weight heparin or heparin-binding peptide covalently attached |
| 10/26/2006 | US20060240092 Polymeric micelles for drug delivery |
| 10/26/2006 | US20060240091 a targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin; for delivering liposomes encapsulating cholinesterase genes particularly the human serum butyryl cholinesterase (Hu BChE) gene as a treatment against nerve agents |
| 10/26/2006 | US20060240084 Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use |
| 10/26/2006 | US20060240080 Alginate sponge and preparation method thereof |
| 10/26/2006 | US20060240073 Collagen and glycosaminoglycan in the form of copolymer, wherein said collagen and said glycosaminoglycan have a 10:1 ratio in weight and said copolymer has a percentage in the range of 0.125% to 8% |
| 10/26/2006 | US20060240070 Delivery of highly lipophilic agents via medical devices |
| 10/26/2006 | US20060240068 Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 10/26/2006 | US20060240064 Medical implants and fibrosis-inducing agents |
| 10/26/2006 | US20060240063 Medical implants and fibrosis-inducing agents |
| 10/26/2006 | US20060240062 Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| 10/26/2006 | US20060240056 Treatment of skin with adenosine or adenosine analog |
| 10/26/2006 | US20060240036 I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis |
| 10/26/2006 | US20060240028 Anti-nls substances and uses thereof in nuclear import inhibition |
| 10/26/2006 | US20060240026 Preventing and/or remedy hematopoietic tumor |
| 10/26/2006 | US20060240023 Apoptosis-associated protein and use thereof |
| 10/26/2006 | US20060240022 Factor involved in metastasis and uses thereof |
| 10/26/2006 | US20060240021 Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes |
| 10/26/2006 | US20060240020 Inhibition of complement activation |
| 10/26/2006 | US20060240019 Antagonists of HMG1 for treating inflammatory conditions |
| 10/26/2006 | US20060240017 IgG4 constant region; antigen-binding Fab' fragment; antibody or antigen binding fragment competitively inhibits binding of A2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha |
| 10/26/2006 | US20060240016 Activity of THAP-family chemokine-binding domains |
| 10/26/2006 | US20060240014 Methods and compounds for the treatment of vascular stenosis |
| 10/26/2006 | US20060240013 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| 10/26/2006 | US20060240011 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 10/26/2006 | US20060240004 Methods for treating tweak-related conditions |
| 10/26/2006 | US20060239998 Prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII; antihemophilic factor inhibitors; monoclonal cell lines expressing such anti-idiotypic antibodies; monoclonal cell lines expressing such anti-idiotypic antibodies |
| 10/26/2006 | US20060239994 Obtained by cloning of cDNA encoding novel human and mouse serine proteases |
| 10/26/2006 | US20060239993 Containing a mutant angiotensin-converting enzyme that releases glycosylphosphatidylinositol-anchored protein from cell surfaces; for treating a prion-related disease, a bacterial infectious disease or male infertility due to sperm-egg binding insufficiency |
| 10/26/2006 | US20060239992 Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |